Profile data is unavailable for this security.
About the company
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
- Revenue in USD (TTM)7.50m
- Net income in USD-345.91m
- Incorporated2000
- Employees358.00
- LocationXenon Pharmaceuticals Inc3650 Gilmore WayVANCOUVER V5G 4W8CanadaCAN
- Phone+1 (604) 484-3300
- Fax+1 (604) 484-3450
- Websitehttps://www.xenon-pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc | 70.85m | -342.60m | 3.00bn | 252.00 | -- | 5.06 | -- | 42.30 | -4.00 | -4.00 | 0.8355 | 7.09 | 0.0863 | -- | -- | 281,146.80 | -41.73 | -44.39 | -44.98 | -47.63 | -- | -- | -483.57 | -1,390.51 | -- | -- | 0.1044 | -- | 23,359.93 | 132.18 | -26.91 | -- | 63.78 | -- |
| Ideaya Biosciences Inc | 218.71m | -113.70m | 3.01bn | 145.00 | -- | 2.94 | -- | 13.78 | -1.30 | -1.30 | 2.46 | 11.65 | 0.1959 | -- | 73.20 | 1,508,345.00 | -10.18 | -18.78 | -10.68 | -20.00 | -- | -- | -51.99 | -185.86 | -- | -- | 0.00 | -- | 3,024.43 | 62.11 | 58.58 | -- | 36.87 | -- |
| Edgewise Therapeutics Inc | 0.00 | -167.80m | 3.09bn | 146.00 | -- | 5.86 | -- | -- | -1.63 | -1.63 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -32.29 | -28.13 | -33.96 | -29.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.40 | -- | 4.75 | -- |
| Spyre Therapeutics Inc | 0.00 | -155.20m | 3.15bn | 102.00 | -- | 5.60 | -- | -- | -2.37 | -2.37 | 0.00 | 9.15 | 0.00 | -- | -- | 0.00 | -22.39 | -53.19 | -24.37 | -59.03 | -- | -- | -- | -3,879.14 | -- | -- | 0.00 | -- | -- | -- | 25.39 | -- | -- | -- |
| Denali Therapeutics Inc | 0.00 | -512.54m | 3.18bn | 503.00 | -- | 3.08 | -- | -- | -2.97 | -2.97 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -40.69 | -25.08 | -44.21 | -29.47 | -- | -- | -- | -348.01 | -- | -- | 0.0055 | -- | -- | -- | -21.23 | -- | 25.15 | -- |
| Legend Biotech Corp (ADR) | 908.96m | -239.70m | 3.30bn | 2.90k | -- | 3.26 | -- | 3.63 | -1.30 | -1.30 | 4.94 | 5.48 | 0.5271 | 13.60 | 936.59 | 349,601.20 | -13.90 | -30.18 | -17.47 | -36.54 | 60.55 | -- | -26.37 | -154.41 | 2.80 | -1.36 | 0.2886 | -- | 119.97 | 59.91 | 65.84 | -- | -18.48 | -- |
| Alumis Inc | 22.12m | -245.15m | 3.51bn | 233.00 | -- | 7.63 | -- | 158.63 | -3.85 | -3.85 | 0.3057 | 3.69 | 0.0491 | -- | 9.28 | 131,672.60 | -54.44 | -- | -61.16 | -- | -- | -- | -1,108.24 | -- | -- | -- | 0.00 | -- | -- | -- | -89.84 | -- | -- | -- |
| Xenon Pharmaceuticals Inc | 7.50m | -345.91m | 3.64bn | 358.00 | -- | 6.02 | -- | 485.72 | -4.36 | -4.36 | 0.0946 | 7.27 | 0.0105 | -- | 5.28 | 20,949.72 | -48.34 | -27.62 | -51.10 | -28.67 | -- | -- | -4,612.13 | -2,733.56 | -- | -- | 0.00 | -- | -- | -25.26 | -47.62 | -- | -21.24 | -- |
| Viking Therapeutics Inc | 0.00 | -359.64m | 3.69bn | 53.00 | -- | 5.74 | -- | -- | -3.18 | -3.18 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -44.29 | -31.71 | -47.32 | -33.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -227.05 | -- | -- | -- |
| BillionToOne Inc | -100.00bn | -100.00bn | 3.81bn | -- | -- | -- | -- | -- | -- | -- | -- | 4.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.75 | -- | 0.238 | -- | 112.72 | -- | 49.72 | -- | -- | -- |
| ACADIA Pharmaceuticals Inc | 1.07bn | 391.00m | 3.84bn | 796.00 | 9.87 | 3.12 | 9.52 | 3.58 | 2.28 | 2.28 | 6.31 | 7.21 | 0.7787 | 3.14 | 9.73 | 1,346,112.00 | 28.42 | 3.92 | 37.60 | 5.17 | 91.69 | 93.59 | 36.49 | 4.59 | 3.71 | -- | 0.00 | 0.00 | 11.87 | 19.39 | 72.66 | -- | 68.65 | -- |
| Gyroscope Therapeutics Holdings Ltd(ADR) | -100.00bn | -100.00bn | 3.93bn | 167.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -70.87 | -- | -58.56 | -- | -- | -- |
| Crinetics Pharmaceuticals Inc | 7.70m | -465.32m | 4.20bn | 594.00 | -- | 3.87 | -- | 545.84 | -4.94 | -4.94 | 0.0818 | 10.38 | 0.006 | -- | 1.71 | 12,956.23 | -36.34 | -36.26 | -38.52 | -38.45 | 66.07 | -- | -6,046.22 | -6,696.84 | 12.30 | -- | 0.00 | -- | 640.71 | 155.27 | -55.93 | -- | 98.71 | -- |
| Erasca Inc | 0.00 | -127.69m | 4.37bn | 103.00 | -- | 11.50 | -- | -- | -0.4506 | -0.4506 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -26.90 | -41.53 | -28.68 | -44.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.28 | -- | -36.84 | -- |
Data as of Mar 03 2026. Currency figures normalised to Xenon Pharmaceuticals Inc's reporting currency: US Dollar USD
51.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 6.20m | 8.03% |
| Avoro Capital Advisor LLCas of 31 Dec 2025 | 5.42m | 7.02% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 4.63m | 6.00% |
| Driehaus Capital Management LLCas of 31 Dec 2025 | 4.54m | 5.87% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.28m | 5.54% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 4.05m | 5.25% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2025 | 3.41m | 4.42% |
| FIAM LLCas of 31 Dec 2025 | 2.72m | 3.52% |
| Polar Capital LLPas of 31 Dec 2025 | 2.47m | 3.19% |
| Braidwell LPas of 31 Dec 2025 | 1.83m | 2.36% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
